Abstract
The 5-year survival rate of osteosarcoma(OS),the most common malignant bone tumor,has remained unchanged at 60%-70%for nearly 40 years.Its treatment mainly relies on surgical resection combined with multi-drug chemotherapy,but it is ineffective for patients with metastasis.In recent years,a series of clinical trials conducted around the world have not effectively improved the 5-year survival rate.However,along with the development of gene sequencing technology and related biomedicines,and the progress of precision medicine,a lot of progress has been made in the research of osteosarcoma driver genes,immune microenvironment,and targeted therapy.In this review,the research progress of osteosarcoma in terms of driver genes,immune microenvironment,and targeted therapy is expounded.
基金项目
国家重点研发计划(2023YFB4706300)
国家重点研发计划(2021YFC2400500)
北京市自然科学基金(L212042)
北京市市属医院科研培育项目(PX2021015)
北京积水潭医院"学科骨干"计划专项(XKGG202105)
北京积水潭医院院级科研基金(2023OSR-GCZX202206)
NETL
NSTL
万方数据